Convalescent Plasma Therapy: a Promising Coronavirus Disease 2019 Treatment Strategy

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2020 Sep 8

PMID 32898468

Citations 12

Authors

Ravikant Piyush

Keshav Rajarshi

Rajni Khan

Shashikant Ray

Affiliations

Soon will be listed here.

Abstract

The world is passing through a very difficult phase due to the coronavirus disease 2019 (COVID-19) pandemic, which has disrupted almost all spheres of life. Globally, according to the latest World Health Organization report (10 August 2020), COVID-19 has affected nearly 20 million lives, causing 728 013 deaths. Due to the lack of specific therapeutic drugs and vaccines, the outbreak of disease has spawned a corpus of contagious infection all over the world, day by day, without control. As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a very rapid infection rate, it is essential to develop a novel ameliorative and curative strategy as quickly as possible. Convalescent plasma (CP) therapy is a type of adaptive immunity that has already been found to be effective in confronting several infectious diseases from the last two decades. For example, CP therapy was used in the treatment of viral-induced diseases like SARS-CoV epidemics, Middle East respiratory syndrome coronavirus (MERS-CoV) pandemics, Ebola epidemics and H1N1 pandemic. In this review, we have mainly focused on the therapeutic role of CP therapy and its neutralizing effect to fight against the COVID-19 outbreak.

Citing Articles

Drummondin E and Flinderole B are potential inhibitors of RNA-dependent RNA polymerase of SARS-CoV-2: an study.

Akhtar N, Verma H, Silkari O, Upadhyay A, Kaushik V, Mannan M BioTechnologia (Pozn). 2023; 103(1):53-70.

PMID: 36605381 PMC: 9642944. DOI: 10.5114/bta.2022.113915.

Arylcoumarin perturbs SARS-CoV-2 pathogenesis by targeting the S-protein/ACE2 interaction.

Singh R, Kumar A, Rane J, Khan R, Tripathi G, Ajay A Sci Rep. 2022; 12(1):17038.

PMID: 36220880 PMC: 9552724. DOI: 10.1038/s41598-022-20759-7.

'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.

Ashique S, Khatun T, Sahu G, Upadhyay A, Adhana A, Kumar S Infect Disord Drug Targets. 2022; 22(8):42-60.

PMID: 35469582 DOI: 10.2174/1871526522666220425103031.

Perplexing issues for convalescent immune plasma therapy in COVID-19.

Ozdemir O North Clin Istanb. 2022; 8(6):634-643.

PMID: 35284793 PMC: 8848483. DOI: 10.14744/nci.2021.73604.

Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS CoV-2 main protease (Mpro) and 3C-like protease for COVID-19 treatment.

Shaik F, Swarnalatha K, Chandra Mohan M, Thomas A, Chikati R, Sandeep G Clin Nutr Open Sci. 2022; 42:62-72.

PMID: 35106518 PMC: 8795779. DOI: 10.1016/j.nutos.2021.12.004.

References

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Sherer Y, Levy Y, Shoenfeld Y . IVIG in autoimmunity and cancer--efficacy versus safety. Expert Opin Drug Saf. 2003; 1(2):153-8. DOI: 10.1517/14740338.1.2.153. View

Hirano T, Murakami M . COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity. 2020; 52(5):731-733. PMC: 7175868. DOI: 10.1016/j.immuni.2020.04.003. View

Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y . Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020; 12(8):6536-6542. PMC: 7202482. DOI: 10.18632/aging.103102. View

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

Beigel J, Voell J, Kumar P, Raviprakash K, Wu H, Jiao J . Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018; 18(4):410-418. PMC: 5871563. DOI: 10.1016/S1473-3099(18)30002-1. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

Murin C, Wilson I, Ward A . Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Nat Microbiol. 2019; 4(5):734-747. PMC: 6818971. DOI: 10.1038/s41564-019-0392-y. View

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

10.

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

11.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

12.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

13.

Zhang H, Zeng Y, Lin Z, Chen W, Liang J, Zhang H . [Clinical characteristics and therapeutic experience of case of severe highly pathogenic A/H5N1 avian influenza with bronchopleural fistula]. Zhonghua Jie He He Hu Xi Za Zhi. 2009; 32(5):356-9. View

14.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

15.

Kim D, Lee J, Yang J, Kim J, Kim V, Chang H . The Architecture of SARS-CoV-2 Transcriptome. Cell. 2020; 181(4):914-921.e10. PMC: 7179501. DOI: 10.1016/j.cell.2020.04.011. View

16.

Katz U, Achiron A, Sherer Y, Shoenfeld Y . Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007; 6(4):257-9. DOI: 10.1016/j.autrev.2006.08.011. View

17.

Hsueh P, Huang L, Chen P, Kao C, Yang P . Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004; 10(12):1062-6. PMC: 7129952. DOI: 10.1111/j.1469-0691.2004.01009.x. View

18.

Casadevall A, Dadachova E, Pirofski L . Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004; 2(9):695-703. DOI: 10.1038/nrmicro974. View

19.

Singhal T . A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4):281-286. PMC: 7090728. DOI: 10.1007/s12098-020-03263-6. View

20.

Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View